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Abstract
This study describes the epidemiology of labora-
tory-confirmed pandemic influenza H1N1 within 
north Queensland, Australia. We collected data 
on all specimens tested for influenza (including 
H1N1) by polymerase chain reaction between 
May and August 2009 at Townsville Hospital. 
Patients requiring admission to hospital and a 
proportion of non-admitted patients had clinical 
characteristics recorded. Multi-variable logistic 
regression analysis was used to identify independ-
ent predictors for admission. Patients requiring 
admission were on average older, less likely to 
be of Aboriginal or Torres Strait Islander descent 
and more likely to be pregnant, female or suffer 
from diabetes mellitus. Oseltamivir provision was 
significantly higher within the Aboriginal or Torres 
Strait Islander patient population. However, when 
the relative sizes of the local Indigenous and non-
Indigenous populations were considered, the 
relative risk of hospital admission for Indigenous 
people was found to be 7.9 (4.7–13.2) in com-
parison to non-Indigenous. Commun Dis Intell 
2010;34(2):102–109.
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Introduction
A novel swine-origin influenza A virus (pandemic 
influenza H1N1 2009, herein referred to as pandemic 
H1N1) was first described from Mexico in April 
2009.1,2 This was associated with reports of patients 
requiring hospitalisation for pneumonia with an 
unexpected increase in mortality and a marked shift 
in age distribution to the 5–59 year age range. This 
contrasted to past epidemics of seasonal influenza 
whereby the greatest morbidity occurred in both those 
under 5 years of age and those older than 65 years.3 
By mid October 2009, more than 414,000 labora-
tory confirmed cases of pandemic H1N1 had been 
recorded worldwide and nearly 5,000 deaths reported 
to the World Health Organization, with these figures 
significantly under-representing the true totals.4
Early surveillance data from the pandemic in 
Australia indicated that the median age of patients 
tested for pandemic H1N1 in Western Australia was 
22 years and in Victoria 21 years, again confirming 
a lower age distribution than that encountered in 
seasonal influenza epidemics.5 However, it has 
been suggested that seasonal H1N1 and influenza 
B exhibit a tendency to infect those with a younger 
median age when compared with seasonal H3N2.6 
Attack rates of seasonal influenza in Australia may 
be as low as 1%.7 Case fatality ratios have been mod-
elled for seasonal influenza and range from 0.14% 
(attack rate of 10%) to 1.4% (attack rate of 1%).5
Obesity and various co-morbidities may also be risk 
factors for severe disease with pandemic H1N1. A 
small subgroup of patients requiring intensive care 
support was described during the early phase of the 
pandemic, with obesity appearing to be associated 
with poor outcome and death.8 Similar studies from 
Australia have described the small but significant risk 
of respiratory failure in relatively young individuals 
with co-morbidities.9 By October 2009, 183 deaths 
have been attributed to pandemic H1N1 in Australia 
with a median age of 53 years in confirmed cases who 
died, compared with 83 years for seasonal influenza 
in the period 2001–2008.10 The burden on intensive 
care units in the region has also been substantial.11
Queensland, Australia, has a unique population 
mix with around 3.3% of the population being 
of Aboriginal and Torres Strait Islander origin, 
with figures of 7.2% seen in the district served 
by Townsville Hospital.12 Indigenous Australians 
are over-represented statistically for a variety of 
co-morbid conditions, with an increasing contri-
bution from chronic non-communicable disease.13 
Indigenous communities from several parts of 
the world appear to have been disproportionately 
affected by the pandemic H1N1 outbreak.14,15 In 
particular, Indigenous Canadians appear to have 
experienced higher rates of severe H1N1.16,17 This 
population is similar to the Australian Aboriginal 
population in that rates of chronic disease are 
between 1.5 and 6.9 times that of non-Indigenous 
Canadians.16,18 In New Zealand, rates of notifica-
tions and hospital admissions for pandemic H1N1 
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are significantly higher in Maori and Pacific 
Islander groups compared with those of European 
or other ethnicities.19
Data are lacking on the real impact of laboratory-
confirmed seasonal and pandemic H1N1 amongst 
Indigenous Australians. Anecdotal local clinical 
experience in north Queensland would suggest that 
this group is numerically over-represented in patients 
presenting with an influenza like illness (ILI). 
During the 1918 pandemic, Indigenous Australian 
populations were severely affected, with some remote 
communities reportedly experiencing high mortal-
ity rates.20 Initial national estimates suggest that 
Indigenous Australians are approximately 10 times 
more likely than non-Indigenous Australians to 
be hospitalised with H1N1, and account for 20% 
of all influenza-related admissions during the ini-
tial months of the current pandemic.10 One study 
estimated the relative risk for hospital admission, 
intensive care requirement and death as 6.6, 6.2 and 
5.2 respectively for Indigenous Australians.21
The aim of this study was to prospectively look 
at all cases of influenza A (pandemic H1N1 and 
seasonal) confirmed at the Townsville Hospital 
laboratory between May and August 2009. The 
investigation aimed to compare admitted and non-
admitted patients with confirmed H1N1 in order 
to identify risk factors for hospital admission, mor-
bidity and mortality, particularly within the local 
Indigenous population.
Methods
This was a prospective study of all laboratory 
confirmed cases of influenza A who were tested 
at Pathology Queensland, Townsville Hospital, 
between April and August 2009. Ethics approval 
was granted by the Human Ethics Committee, 
Townsville Health Service District.
Location
Townsville Hospital is located within the tropi-
cal region of north Queensland. During the study 
period it remained the only local facility to offer on-
site molecular diagnostic services for influenza. The 
laboratory receives specimens from hospitals and 
clinics over a large and diverse geographical area, 
covering a population of approximately 216,480.22
Subjects and design
All subjects who presented with an influenza-like 
illness between May and August 2009 and who 
subsequently had a respiratory specimen (nose 
and throat swab, endotracheal aspirate, bron-
choscopic aspirate or nasopharyngeal aspirate) 
that tested positive for influenza A by nucleic 
acid amplification were included in the primary 
analysis. Subsequently, all admitted patients and a 
proportion of non-admitted H1N1 positive control 
patients were included in a comparative analysis. 
The number of non-admitted control subjects with 
clinical data collected was intended to match those 
admitted at a ratio of approximately 2:1. Data rep-
resenting non-admitted patients with H1N1 were 
obtained from those tested and discharged from the 
Townsville emergency department, district hospi-
tals (mainly Charters Towers and Palm Island) and 
a local general practitioner practice. Data could not 
be obtained for all non-admitted H1N1 positive 
patients, primarily as a result of the practical dif-
ficulties in accessing clinical notes from a diverse 
group of geographically isolated testing facilities.
Data collection
Demographic and laboratory data were collected 
on all patients tested. This included age, sex, indig-
enous status, need for admission and sub-typing 
of influenza A. Self-reported indigenous status is 
routinely collected at the time of registration in the 
laboratory database. For the comparative analysis, 
clinical data were ascertained by chart review of all 
admitted and a selection of non-admitted patients. 
The following variables were collected from both 
groups: pregnancy, the presence of co-morbid medi-
cal conditions (obesity, chronic lung, renal or cardi-
ovascular disease, diabetes mellitus, malignancy or 
immunosuppression), commencement of antiviral 
agents, need for intensive care unit (ICU) admis-
sion and clinical outcome. Obesity was defined as 
a body mass index of above 30 kg/m2. The term 
‘chronic lung disease’ incorporated the diagnoses of 
asthma, chronic obstructive pulmonary disease and 
other conditions leading to significant respiratory 
compromise. Chronic renal failure was defined as 
an estimated glomerular filtration rate (GFR) of less 
than 60 mL per minute over a period of 3 months 
or longer. The definition of immunosuppression 
included the administration of long term systemic 
corticosteroids or immunosuppressive medications 
or HIV infection.
Laboratory diagnosis
Detection of influenza A was performed as previ-
ously described.23 Briefly, this was a 5’-nuclease 
real-time polymerase chain reaction (RT-PCR) 
(WhSl-FluA-5N), which had been developed 
for the detection of influenza type A. This test 
utilised conserved primer and probe targets on 
the matrix protein genes of a broad range of 
influenza A subtypes, including avian influenza 
subtypes. Using this information, 2 primers and 
one 5’-nuclease probe were designed. By testing 
10-fold dilutions of H1N1 and H3N2 strains, 
the detection limit of the WhSl-FluA-5N assay 
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was determined to be 1 TCID50 per millilitre for 
both viral types. Subsequent typing as pandemic 
H1N1 was performed as described by Whiley et 
al.24 Two assays were used. These were H1-PCR 
and N1-PCR, targeting the novel influenza A 
(H1N1) virus haemagglutinin and neuramini-
dase genes, respectively.
Statistical analysis
Numerical variables were described using median 
values, inter-quartile ranges (IQR) and ranges, 
because their distribution was skewed. Only patients 
with complete clinical data recorded were included in 
the analysis. Patients admitted to hospital were com-
pared with patients who were not admitted regard-
ing patient characteristics using non-parametric 
Wilcoxon tests, Chi-square tests, Fisher’s exact test, 
and Spearman rank correlation coefficient.
Multi-variable logistic regression analysis was used to 
identify independent predictors of being admitted to 
hospital. For this analysis, all variables were dummy 
coded. Age was categorised using the quartiles of the 
distribution. Stepwise forward and backward selec-
tion procedures were used. After a stable model was 
identified all remaining characteristics were consid-
ered as potential confounders. A characteristic was 
considered a confounder if the estimate changed by 
5% or more. Results are presented as odds ratios and 
95% confidence intervals. This analysis was repeated 
for female patients only. Throughout the analysis 
a significance level of 0.05 was assumed. Statistical 
analysis was conducted using SPSS for Windows, 
version 17.0 (SPSS Inc., Chicago, Illinois). We esti-
mated the cumulative incidence of outcomes relating 
to hospital admissions, intensive care and death 
during the study period. To calculate the relative 
risk (RR) for both Indigenous and non-Indigenous 
groups we compared the cumulative incidence of the 
outcomes for each group with the same outcome in 
the total population minus the population at risk. 
The proportion of Indigenous people within the local 
population was estimated as 7.2% from Australian 
census data.22
Results
During May to August 2009, 1,779 respiratory 
specimens were tested for influenza A from subjects 
with an ILI. A total of 414 (23.3%) tested positive 
for influenza A by PCR. Of these, 360 (87%) were 
positive for pandemic H1N1. A total of 61 (17%) 
patients required admission to hospital with 5 deaths 
(1.4%). Complete clinical data were available for 
181 (50.3%) H1N1 positive subjects (Figure 1).
Within the group of patients for which complete 
clinical data were available (n = 181), the median 
duration of stay in hospital was 3 days (IQR = 2 
to 7 days; range 1 to 30 days). A majority (77.8%) 
of cases were Townsville residents, including 
34 patients from Palm Island. Single cases came 
from Mackay, Ayr and Cairns, while 17 patients 
were resident in Charters Towers. The Townsville 
Hospital Emergency Department was the primary 
testing site in most cases (43.6%). The median 
age of recorded cases was 21 years (IQR = 9.5 to 
39.5 years; range 0.2 to 90 years), 47.5% were male 
and 52.5% were Indigenous (Table 1).
Associations with being admitted to hospital
H1N1 positive cases admitted to hospital were on 
average older (median age 33 versus 15.5 years), 
less likely to be Indigenous (37.7% versus 60.3%), 
and more likely to have diabetes mellitus (24.6% 
versus 4.2%) compared with cases who were 
not admitted (Table 2). Multi-variable logistic 
regression analysis showed that patients with 
diabetes mellitus were 6.6 times more likely to be 
admitted to hospital than people without diabe-
tes (P = 0.005) (Table 2). Patients of Indigenous 
descent were 0.3 times likely (that is, non-
Figure 1:  Summary of study design and patient selection
Respiratory specimens tested for Influenza  by PCR (n=1779)  
Positive for Influenza A 
by PCR (n=414) 
Positive for Pandemic H1N1  
by PCR (n=360)  
Admitted to hospital  (n=61) Not admitted (n=299) 
 
Complete clinical data available (n=61) Complete clinical data available (n=120) 
Demographic analysis 
Comparative analysis 
Laboratory analysis 
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Indigenous patients were 3.2 times more likely) 
to be admitted to hospital than non-Indigenous 
patients (P = 0.003).
Multi-variable regression analysis for female 
patients only, showed that pregnant women were 
5.8 times more likely to be admitted to hospital 
compared with women who were not pregnant 
(P = 0.007) (Table 3). Women with diabetes mel-
litus were 9.1 times more likely to be admitted to 
hospital compared with women without diabetes 
(P = 0.016).
There was a linear trend towards higher admission 
rates for older patients (Spearman’s correlation 
coefficient = 0.68; P = 0.021) (Figure 2). Of the 
27 patients aged 5 years or younger, 33.3% were 
admitted to hospital; while of the 16 patients aged 
41 to 50 years, 25% were admitted to hospital.
Indigenous patients
Indigenous subjects were significantly more likely 
than non-Indigenous, to have at least 1 significant 
clinical co-morbidity (74.4% vs. 53.8%; OR 2.501 
(1.51-4.16); P = 0.0003), as might be expected 
for this population. This was particularly so with 
diabetes where 12% of H1N1 positive Indigenous 
subjects had diabetes compared with 3% of non-
Indigenous (OR 4.23 (1.49-11.98); P = 0.0045). 
Table 1:  Basic characteristics overall and stratified by admission of 181 H1N1 positive cases
Total 
(n = 181)
Not admitted 
(n = 120)
Admitted (n = 61) P-value
Median age (IQR); range (years) 21 (9.5, 39.5); 
range 0.2 to 90
15.5 (8.25, 26.75); 
range 0.75 to 61
33 (15.5, 53.0); 
range 0.2 to 90
P < 0.001
% Male 47.5 46.7 49.2 P = 0.749
% Aboriginal and Torres Strait Islander 52.5 60.3 37.7 P = 0.004
% Townsville resident 77.8 78.2 77.0 P = 0.866
% Females who were pregnant 15.1 (n = 93) 8.1 (n = 62) 29.0 (n = 31) P = 0.013
Median gestation week of pregnant females 
(IQR); range (weeks)
33 (22.75, 37.25); 
range 12 to 40; 
(n = 14)
32 (14, 36); range 
12 to 38; (n = 5)
36 (27, 38); range 
22 to 40; (n = 9)
P = 0.298
% Diabetes mellitus 11.0 4.2 24.6 P < 0.001
% Lung disease 29.8 27.5 34.4 P = 0.336
% Renal disease 8.3 3.3 18.0 P = 0.001
% Cardiac disease 14.4 8.3 26.2 P = 0.001
% With malignancy 2.8 0.8 6.6 P = 0.045
% Immunosuppressed 5.0 2.5 9.8 P = 0.063
% Obese 16.1 10.0 28.3 P = 0.002
Table 2:  Independent factors associated with admission to hospital. Results of multi-variable 
logistic regression analysis based on 177* H1N1 positive cases
Not admitted 
(n = 116)
Admitted (n = 61) Odds-ratio 
(95% CI)†
P-value
Age Continuous 1.02 (1.00, 1.04) P = 0.042
Being Aboriginal or Torres Strait 
Islander
No 46 38 1 P = 0.003
Yes 70 23 0.31 (0.14, 0.68)
Diabetes mellitus
No 111 46 1
Yes 5 15 6.6 (1.8, 25.0) P = 0.005
* Four cases had missing values for ethnicity.
†	 95%	confidence	interval;	the	model	was	adjusted	for	the	confounding	effects	of	gender.
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Of the 91 pregnant women with H1N1, 11 (12%) 
were Indigenous, of which four were admitted. Of 
the admissions to ICU, only two were Indigenous 
and neither of these died. There was a single death 
within the Indigenous group, in an elderly patient 
with multiple co-morbidities.
Neuraminidase inhibitor use
Oseltamivir was the only recorded anti-viral agent 
prescribed. Rates of oseltamivir provision were sig-
nificantly greater in Indigenous patients. Seventy-
nine per cent (n = 81) of non-Indigenous patients 
received antiviral drugs compared with 93.5% of 
those of Aboriginal and Torres Strait Island origin 
(n = 93) (OR 3.9 (1.4- 10.3); P = 0.005).
Outcome
Overall, 9 cases (5.0%) were treated in ICU and 
8 cases (4.4%) required ventilation for a median 
time of 7 days (range 4–12 days). Five cases died, 
2 cases required extracorporeal membrane oxy-
genation (ECMO), 1 case developed encephalitis, 
1 pregnant woman lost her foetus but recovered her-
self, 2 pregnant women required a lower segment 
Caesarian section at term and 2 cases were still in 
ICU when data were retrieved. There was also one 
death from seasonal influenza A and Staphylococcus 
aureus pneumonia in a young non-Indigenous 
patient with a history of intravenous drug use.
Cumulative incidence of hospitalisation, 
intensive care admission and death for 
Indigenous populations
Estimations of the RR for hospital admission, inten-
sive care and death for Indigenous Australians were 
7.85 (4.7-13.2), 3.7 (0.8-17.8) and 3.24 (0.4-29.0) 
respectively in comparison with the non-Indigenous 
population. The wide confidence intervals for the 
latter 2 figures reflect the small numbers involved 
(Table 4).
Discussion
The current pandemic of H1N1 influenza was first 
reported to disproportionately affect Indigenous 
populations in Canada.16 The Indigenous Australian 
population is similar in relation to the presence 
of co-morbidities such as diabetes, chronic renal, 
respiratory and cardiac disease. The study reported 
here, is the first to describe the impact of pandemic 
H1N1 influenza on the Indigenous population of 
north Queensland. The co-morbidities described 
conform to those expected throughout Indigenous 
populations in Australia. Despite making up 
approximately 7% of the local population, 34.7% 
(125/360) of all H1N1 positive specimens were 
from Indigenous subjects.
Patients admitted for pandemic H1N1 appeared 
less likely to be Indigenous in the comparative 
analysis. This finding appeared counter-intuitive 
given the well-described burden of co-morbidity 
within this population.13 This result may reflect 
Table 3:  Independent factors associated with admission to hospital. Results of multi-variable 
logistic regression analysis based on 93* female H1N1 positive cases
Not admitted (n = 62) Admitted (n = 31) Odds ratio (95% CI)† P-value
Being pregnant
No 57 22 1 P = 0.007
Yes 5 9 5.8 (1.6, 20.6)
Diabetes mellitus
No 59 23 1 P = 0.016
Yes 3 8 9.1 (1.5, 55.0)
* Two cases had missing values for being pregnant.
†	 95%	confidence	interval;	the	model	was	adjusted	for	the	confounding	effects	of	age	and	ethnicity.
Figure 2:  Association between age and 
percentage of cases admitted to hospital for 
pandemic H1N1
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bias within the data whereby a greater proportion 
of Indigenous patients were represented within 
the non-admitted group. This could have resulted 
from the overuse of emergency services (the pri-
mary point of testing in most cases), the public 
health emphasis for testing in Indigenous popula-
tions (during the ‘Protect’ phase of the pandemic 
introduced locally on 22 June 200925) and the pre-
dominance of clinical data available (and therefore 
inclusion in the study) from certain health services 
such as Palm Island. When the relative population 
sizes are taken into account a cumulative inci-
dence of 148.4 per 100,000 for admission within 
the Aboriginal and Torres Strait Island group can 
be estimated and compared with a rate of 18.9 per 
100,000 in the non-Aboriginal and Torres Strait 
Island group. These figures then translate into a 
significantly elevated relative risk of admission for 
Indigenous patients with H1N1. These results are 
broadly in agreement with previously published 
data analysed in a similar way.21
Despite the relatively young age of patients 
admitted in comparison with previous influenza 
seasons, increasing age remains a predictor of 
admission with a linear relationship seen in com-
parison with the proportion of those admitted. 
Equally, the under 5 year group were more likely 
to be admitted (33% admitted in this age range). In 
Australia, an average of 3,000 excess deaths a year 
may be attributable to influenza in people who 
are at least 50 years of age, with at least 85% of 
these occurring in people 65 years of age or older. 
Many of these would have underlying medical 
conditions.26 Increasing age was associated with 
increasing co-morbid conditions and may account 
for the relationships seen (Figure 3). The presence 
of diabetes mellitus provided a strong predictor 
of requirement for admission. Diabetes has been 
described as occurring in up to 15% of hospitalised 
patients with H1N1 in the United States,27 second 
only to asthma in frequency. Diabetes has long 
been thought to increase the risk of complications 
in seasonal influenza.28 Whether this occurs as a 
product of diabetes itself, from increased risk of 
secondary bacterial infection, through co-existing 
cardiovascular mortality or via other factors 
remains to be clarified. There has been increasing 
awareness of the potential links between influenza 
and cardiovascular disease and cardiac death.29
Pregnancy was overrepresented in admitted patients 
with no significant difference being seen between 
Indigenous and non-Indigenous women. A total of 
12 pregnant women required admission to hospital 
for H1N1 in this period (16% of all H1N1 admis-
sions). Two of these subsequently required ICU 
management and, although neither died, one suf-
fered a stillbirth. However, whether higher rates of 
admission in pregnancy reflect the presence of more 
severe respiratory disease or greater vigilance by 
clinicians (given the publicised concerns within this 
group) cannot be concluded from this study.
Table 4:  Estimated relative risk of the cumulative incidence of hospitalisation, Intensive Care 
Unit (ICU) admission or death in relation to pandemic H1N1 for Aboriginal and Torres Strait 
Islander and non-Indigenous populations within the Townsville Health Services district
Outcome measure Number Population at risk Rate per 100,000 RR 95% confidence interval
Hospitalisation total 61 216,480 28.2
ICU admission total 9 216,480 4.2
Death total 5 216,480 2.3
Hospitalised Indigenous 23 15,500 148.4 7.85 4.7–13.2
Hospitalised non-Indigenous 38 200,980 18.9
ICU Indigenous 2 15,500 12.9 3.70 0.8–17.8
ICU non-Indigenous 7 200,980 3.5
Death Indigenous 1 15,500 6.5 3.24 0.4–29.0
Death non-Indigenous 4 200,980 2.0
Figure 3:  Relationships between age, diabetes 
mellitus and hospital admission for pandemic 
H1N1
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Whether older patients, those that were pregnant 
or those with diabetes developed more severe dis-
ease or were more likely to be admitted as a result 
of their co-morbid conditions alone is not clear. 
However, the pandemic response team within the 
hospital maintained a policy of encouraging medi-
cal staff to only admit patients with clear evidence 
of complicated disease (e.g. hypoxia, tachypnoea, 
abnormal chest signs, etc) rather than admit-
ting due to the presence of co-morbidities alone. 
Patients not demonstrating these adverse clinical 
features were usually tested, started on oseltamivir 
and discharged with advice to return if symptoms 
deteriorated. As such, admission to hospital should 
remain a reasonable, although imperfect, surrogate 
marker of disease severity.
There were a total of 6 deaths in hospitalised 
patients attributable to influenza A during this 
period, of which five were confirmed H1N1 and 
one seasonal influenza A. Given that the number 
testing positive for H1N1 at our laboratory would 
grossly underestimate the total number infected in 
the community as a whole, the overall number of 
deaths and ICU admissions attributable to H1N1 
was relatively low.
The early use of oseltamivir had initially been 
encouraged, on the basis of published papers, to 
reduce the duration of symptoms, transmissibil-
ity and possibly the likelihood of severe lower 
respiratory tract infection.30 Oseltamivir use was 
significantly higher within the Aboriginal and 
Torres Strait Island group in comparison to non-
Indigenous patients. Taken in conjunction with 
the relatively low rates of adverse outcomes in this 
group, the possibility is raised that widespread 
antiviral use ameliorated the anticipated impact 
of pandemic H1N1. However, this conclusion 
cannot be drawn with confidence from the data 
presented here.
Limitations of this study are acknowledged. Firstly 
only patients tested for influenza were included, 
but not all patients with ILI. With the progres-
sion of the pandemic, national and state protocols 
defined testing to be restricted to ‘at risk’ groups 
or those with severe disease manifestations. As 
such, numbers tested will greatly underestimate 
the true incidence of H1N1 within the commu-
nity and ‘at-risk groups’ will be over-represented. 
However, we maintained a relatively liberal test-
ing protocol during this time and continued to 
receive and process specimens from ‘low-risk’ 
individuals. Complete clinical data were not 
available for approximately 50% of non-admitted 
H1N1 positive patients. We attempted to obtain a 
representative sample of these, however, we can-
not be certain that significant clinical differences 
exist between these included patients and those for 
whom data were not available. Furthermore this 
study only described the experience from a single 
centre, with relatively small numbers involved. 
Nonetheless, given these caveats, we believe that 
the findings presented here provide some insight 
into the effects of pandemic influenza H1N1 on 
Indigenous communities of north Queensland, 
especially given the paucity of accurate data in 
this area.
In summary, we describe the basic epidemiology 
of laboratory-confirmed pandemic H1N1 cases 
from north Queensland. Comparison with non-
admitted patients with H1N1 suggested that those 
admitted were older, more likely to have diabetes 
mellitus and be non-Indigenous. Pregnancy also 
appeared to be strongly associated with probability 
of admission. However, the robustness of these 
findings are tempered by the possibility that sig-
nificant ascertainment bias may exist within the 
data. Estimations of the cumulative incidence for 
H1N1 within the respective populations demon-
strated that the relative risk for admission within 
the Aboriginal and Torres Strait Island group was 
higher (RR = 7.9 (4.7-13.2)) than for the non-Abo-
riginal and Torres Strait Island group. However, 
the overall numbers within the Aboriginal and 
Torres Strait Island group of ICU admission and 
death were small.
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